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Venous thromboembolism (VTE), blood clots occurring as deep vein thrombosis, pulmonary 
embolism, or both, is an important and growing public health issue. The precise number of 
people affected by VTE is unknown; however, estimates suggest that up to 900,000 events 
resulting in as many as 100,000 premature deaths occur in the United States yearly with 
healthcare costs as high as $10 billion.1–3 Although anyone can develop VTE, research has 
shown that half of VTE events occurring in the outpatient setting are directly linked to a 
recent hospitalization or surgery.4 In patients with cancer, VTE is a leading cause of death 
after the cancer itself.5,6 Fortunately, many of these healthcare-associated VTE (HA-VTE) 
cases can be prevented. Recent analyses have shown that as many as 70% of HA-VTE cases 
are preventable through appropriate prophylaxis,7–9 yet reports suggest that fewer than half 
of hospital patients receive VTE prophylaxis in accordance with accepted evidence-based 
guidelines.10 Appropriate prevention of HA-VTE can result in a significant reduction in 
overall VTE occurrence, thereby decreasing healthcare burden and unnecessary deaths.
In November 2015, the Centers for Disease Control and Prevention (CDC) released the 
Healthcare-Associated VTE Prevention Challenge (http://www.cdc.gov/ncbddd/dvt/ha-vte-
challenge.html) to identify, highlight, and reward hospitals, managed care organizations, and 
hospital networks that implemented innovative, effective, and sustainable strategies to 
prevent HA-VTE.
This issue of the Journal of Hospital Medicine showcases the initiatives of several of the 
CDC’s HA-VTE prevention champions. These champions range from a small community 
hospital to some of the country’s largest health systems, and they represent both rural and 
urban areas. Together they cared for more than 450,000 patients admitted to hospitals across 
the United States in 2014. They were able to improve VTE prevention within their 
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institutions and organizations by implementing successful and sustainable VTE prevention 
strategies such as engaging teams of different healthcare experts to support and promote 
prevention activities, informing patients and providers about the need for and benefits of 
VTE prevention, and using technology (such as electronic risk assessment and clinical 
decision support tools and alerts) to ensure that all patients are assessed for their risk for 
VTE and bleeding. These tools also help ensure that patients, when appropriate, are provided 
with and use appropriate prevention measures for their level of risk. Moreover, they provided 
real-time feedback, scorecards, and dashboards for providers and organizations to monitor 
performance and identify areas for improvement.
The CDC and the Agency for Healthcare Research and Quality (AHRQ) are partnering to 
disseminate and promote these best practices. In addition to this challenge, the CDC, AHRQ 
and the Joint Commission Center for Transforming Healthcare are working on activities and 
programs dedicated to improving prevention of HA-VTE. These are summarized below.
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY
The AHRQ works to reduce the incidence of VTE among patients at risk of developing the 
condition by conducting research and providing support for quality-improvement efforts. In 
2008, AHRQ published an evidence-based resource for prevention of VTE based on quality-
improvement principles that were successfully applied by the University of California, San 
Diego Medical Center, and Emory University Hospitals in an AHRQ-funded research 
project. This resource, Preventing Hospital-Acquired Venous Thromboembolism: A Guide 
for Effective Quality Improvement, was updated in 2014 and is available at http://
www.ahrq.gov/professionals/quality-patient-safety/patient-safety-resources/resources/
vtguide/index.html. The guide is intended to assist quality-improvement practitioners who 
wish to improve prevention of HA-VTE in their own organizations.
Since its original release, hospital quality-improvement teams have used the guide to close 
the gap between available evidence about how to prevent VTE and successful 
implementation of that knowledge so that hospitals can improve care as effectively and 
efficiently as possible. The guide includes examples of risk assessment methodologies and 
evaluation metrics along with other key elements that help front-line providers establish or 
enhance VTE prevention programs.
AHRQ maintains an active patient safety program that spans a wide range of patient safety 
problems including VTE that is aimed at making healthcare safer. The AHRQ works with 
many different healthcare stakeholders to (1) better understand threats to patient safety and 
(2) develop and refine strategies that put this knowledge to work to prevent patient harm. For 
example, the AHRQ provides extramural research grants to investigators studying new 
methods of identifying patients at risk for VTE and ways to improve VTE prophylaxis in 
hospital patients undergoing medical treatment and surgical procedures.
In addition to a collaborative partnership with the CDC on the 2015 Healthcare-Associated 
VTE Prevention Challenge, the AHRQ also partners with other federal agencies and is an 
active contributor to the Department of Health and Human Services National Action Plan for 
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Adverse Drug Event Prevention. The plan outlines opportunities to advance patient safety 
through the prevention of adverse drug events and the promotion of medication safety 
among 3 drug classes including anticoagulants, a key component for VTE prevention. 
Patients and their families are critically important partners for improving patient safety, and 
the significant potential for their impact is represented by the AHRQ tools and resources 
such as an information video and guide for patients about the safe use of blood thinners 
(http://www.ahrq.gov/patients-consumers/diagnosis-treatment/treatments/btpills/
btpills.html).
THE JOINT COMMISSION CENTER FOR TRANSFORMING HEALTHCARE
The Joint Commission Center for Transforming Healthcare commenced the Preventing 
Venous Thromboembolism project in October 2014, with 5 participating hospitals and health 
centers in collaboration with the CDC. The hospitals and health centers participating on this 
project include: Cleveland Clinic, The Johns Hopkins Hospital, Kaiser Permanente South 
Bay Medical Center, Massachusetts General Hospital, and Texas Health Resources.
Often, VTE risk factors are not consistently assessed across all hospital patients, and there is 
much variation to the selection of appropriate mechanical and/or pharmacological 
prophylaxis. In addition, the current accepted guidelines are not implemented consistently 
across hospitals. VTE rates can be reduced with accurate risk assessment and appropriate 
utilization of pharmacological and/or mechanical prophylaxis. However, there are multiple 
barriers to consistent, successful implementation of preventative measures. During the first 
year of this project, the participants utilized Robust Process Improvement, a fact-based, 
systematic, and data-driven problem-solving methodology that incorporates tools and 
concepts from Lean, Six Sigma, and change management, to assist them in identifying the 
root causes and barriers to preventing VTE in at-risk patients.
Aggregate preliminary findings show that some of the contributing factors to VTE 
prevention included issues with staff attitudes and beliefs, staff and patient education, risk 
assessments, order sets, ineffective mechanical and pharmacological prophylaxis, and patient 
refusal. The participating organizations are currently developing and implementing solutions 
targeted to their specific root causes. The solutions will be tested, validated, and then spread 
to other healthcare organizations. Project findings are tentatively scheduled for release in 
2017.
The Joint Commission has been committed to preventing VTE for over a decade, beginning 
with the development of the VTE measures, which were the result of the National 
Consensus Standards for the Prevention and Care of Deep Vein Thrombosis project with the 
National Quality Forum that formally began in January 2005. In addition, The Joint 
Commission and Joint Commission Resources have also aimed to reduce harm and improve 
the quality of care for VTE patients through the Hospital Engagement Network 
collaborative, publications related to improving VTE patient safety, and research on 
improving transitions of care and discharge instructions for patients with VTE.
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CENTERS FOR DISEASE CONTROL AND PREVENTION
The CDC’s Division of Blood Disorders works to prevent VTE and to reduce sickness and 
death among those who develop VTE. The CDC’s primary VTE activities focus on 
developing improved methods and innovative tools for monitoring and understanding VTE 
occurrence and the effectiveness of VTE prevention activities, conducting epidemiologic 
studies on the causes and outcomes of VTE and its complications, and working internally 
and with partners to develop and promote education and awareness materials to inform the 
public and healthcare providers about the importance of knowing VTE risk factors to 
improve prevention, and the importance of knowing the signs and symptoms of VTE to 
ensure early and accurate diagnosis and treatment of VTE. Recently, the CDC collaborated 
with the National Blood Clot Alliance, through their Stop the Clot, Spread the Word 
Campaign, to develop and promote prevention of VTE among hospitalized patients (https://
www.stoptheclot.org/spreadtheword). To learn more about the CDC’s VTE programs please 
visit http://www.cdc.gov/ncbddd/dvt/index.html.
The CDC, AHRQ, and The Joint Commission hope that readers will find the successes of 
the HA-VTE Prevention Champions’ initiatives informative and encouraging. They are 
examples of how any healthcare setting, from a small hospital to a large healthcare system, 
can implement approaches and tools to improve prevention of HA-VTE.
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